Eli Lilly (LLY) says it can overcome high-quality problem of too much demand

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. 

Brendan McDermid | Reuters

Eli Lilly‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply.

Hello friends, my name is Amit Sharma, I am the Writer and Founder of this blog and share all the information related to Blogging, SEO, Internet, Review, WordPress, Make Money Online, News and Technology through this website.🔁

Leave a Comment